Works Cited

1. Brenner BM (ed). Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Elsevier; 2016.

2. Levine DZ. Caring for the Renal Patient. 3rd ed. Philadelphia, PA: Saunders; 1997.

3. Mandal AK. Hypokalemia and hyperkalemia. Med Clin North Am. 1997;81(3):611-639.

4. Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS. Harrison's Principles of Internal Medicine. 19th ed. New York, NY: McGraw-Hill; 2015.

5. Barker LR, Fiebach NH, Kern DE, et al (eds). Principles of Ambulatory Medicine. 7th ed. Baltimore, MD: Lippincott, Williams and Wilkins; 2007.

6. MedlinePlus. Potassium Test. Available at Last accessed April 23, 2018.

7. Merck Manual. Hypokalemia. Available at Last accessed April 23, 2018.

8. Garth D. Hypokalemia in Emergency Medicine. Available at Last accessed April 23, 2018.

9. Lederer E, Alsauskas ZC, Mackelaite L, Nayak V. Hyperkalemia. Available at Last accessed April 23, 2018.

10. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551.

11. Abbas S, Ihle P, Harder S, Schubert I. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. Pharmacoepidemiol Drug Saf. 2015;24(4):406-413.

12. Vardeny O, Claggett B, Anand I, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7(4):573-579.

13. Desai AS, Liu J, Pfeffer MA, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018; [Epub ahead of print].

14. Greenberg A. Primer on Kidney Diseases. 5th ed. Philadelphia, PA: Saunders; 2009.

15. Velickovic-Radovanovic RM, Mitic B, Kitic D, Kostic S, Cvetkovic T, Djordjevic V. Acute renal failure after licorice ingestion: a case report. Cent Eur J Med. 2010;6(1):113-116.

16. Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26(3):377-384.

17. Tamargo J. New Drugs for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors: Hype or Hope? Available at Last accessed April 23, 2018.

18. Frassetto LA, Lo LJ. Bartter Syndrome. Available at Last accessed April 23, 2018.

19. Dunn RL. Exposure to trimethoprim-sulfamethoxazole is associated with hospitalisation for hyperkalemia in older people with spironolactone. Evid Based Med. 2012;17(4):130-131.

20. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156-e166.

21. Lexicomp Online. Available at Last accessed April 23, 2018.

22. Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusion. Arch Intern Med. 1990;150(3):613-617.

23. Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension.Am Heart J. 2005;150(3):426-433.

24. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21(5):733-735.

25. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J. 2006;33(1):40-47.

26. U.S. Food and Drug Administration. FDA Approves New Drug to Treat Hyperkalemia. Available at Last accessed April 23, 2018.

27. Kovesdy CP. Management of hyperkalemia: an update for the internist. Am J Med. 2015;128(12):1281-1287.

28. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151-161.

29. Wie MR, Mayo MR, Garza D, et al. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. J Hypertens. 2017;(Suppl 1):S57-S63.

30. Montaperto AG, Gandhi MA, Gashlin LZ, Symoniak MR. Patiromer: a clinical review. Curr Med Res Opin. 2016;32(1):155-164.

31. Meaney CJ, Beccari MV, Yang Y, Zhao J. Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherpy. 2017;37(4):401-411.

32. Sarafidis PA, Georgianos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother. 2015;16(14):2205-2215.

33. Hollander-Rodriguez JC, Calvert JF. Hyperkalemia. Am Fam Physician. 2006;73(2):283-290.

34. Family Practice Notebook. Hyperkalemia Management. Available at Last accessed April 23, 2018.

35. Griffing GT, Odeke S, Nagelberg SB. Addison Disease. Available at Last accessed April 23, 2018.

36. National Kidney and Urologic Diseases Information Clearinghouse. Renal Tubular Acidosis. Available at Last accessed April 23, 2018.

37. Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. JASN. 2002;13(8):2160-2170.

38. Chrousos GP, Sertedaki A, Kyritsi EM. Hyperaldosteronism. Available at Last accessed April 23, 2018.

Evidence-Based Practice Recommendations Citations

1. Management of Chronic Kidney Disease Working Group. VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care. Washington, DC: Department of Veterans Affairs, Department of Defense; 2014. Summary retrieved from National Guideline Clearinghouse at Last accessed May 11, 2018.

Copyright © 2018 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.